Multiple Sclerosis Treatment Market Report 2026

The multiple sclerosis treatment market size has grown strongly in recent years. It will grow from $26.13 billion in 2025 to $27.44 billion in 2026 at a compound annual growth rate (CAGR) of 5%. The growth in the historic period can be attributed to autoimmune disease research, injectable ms therapies, neurology clinic expansion, hospital-based treatment, biologics development.

The multiple sclerosis treatment market size is expected to see steady growth in the next few years. It will grow to $33.02 billion in 2030 at a compound annual growth rate (CAGR) of 4.7%. The growth in the forecast period can be attributed to oral therapy adoption, home-based ms care, long-term disease management, advanced imaging diagnostics, personalized immunotherapy. Major trends in the forecast period include expansion of disease-modifying therapies, growth of oral ms medications, increased focus on early diagnosis, rising use of monoclonal antibodies, personalized treatment approaches.

The increasing prevalence of neurological disorders is anticipated to drive the growth of the multiple sclerosis treatment market in the coming years. Neurological disorders are medical conditions that impact the brain, spinal cord, and peripheral nerves, resulting in impairments related to movement, communication, behavior, or other bodily functions. The rise in neurological disorders is largely attributed to the aging population, as extended life expectancy increases the likelihood of age-related conditions such as Alzheimer’s disease. Multiple sclerosis treatments support the management of neurological disorders by modulating the immune system to reduce inflammation, limit nerve damage, and ease symptoms, thereby enhancing patients’ quality of life. For instance, in October 2023, according to the World Federation of Neurology, a UK-based association of national neurological societies, over 40% of the global population currently experiences some form of neurological condition, and this burden is projected to nearly double by 2050. Therefore, the growing prevalence of neurological disorders is fueling the growth of the multiple sclerosis treatment market.

Major companies operating in the multiple sclerosis treatment market are focusing on the development of advanced therapies, such as monoclonal antibody drugs, to improve treatment effectiveness and patient outcomes. Monoclonal antibody drugs are laboratory-engineered molecules designed to target specific antigens, and in multiple sclerosis, they function by reducing inflammation and preventing immune cells from attacking nerve fibers, thereby slowing disease progression. For example, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (ocrelizumab) for the treatment of multiple sclerosis (MS). This drug targets CD20-positive B cells, helping to reduce inflammation and nerve damage associated with MS. It is the first therapy approved for both relapsing and primary progressive forms of MS, significantly lowering relapse rates and slowing disability progression, while offering the convenience of twice-yearly infusions.

In March 2024, Juvisé Pharmaceuticals, a France-based pharmaceutical company, acquired a multiple sclerosis drug from Actelion Pharmaceuticals Ltd. for an undisclosed amount. Through this acquisition, Juvisé Pharmaceuticals aims to broaden its neurology portfolio beyond the US and Canada, while also opening its capital to Bpifrance and Pemberton to support future growth initiatives. Actelion Pharmaceuticals Ltd. is a Switzerland-based pharmaceutical company actively involved in the development and treatment of multiple sclerosis.

Major companies operating in the multiple sclerosis treatment market are Biogen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi Genzyme, Merck KGaA, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson (Janssen), TG Therapeutics Inc., Acorda Therapeutics Inc., Takeda Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Almirall S.A., Otsuka Pharmaceutical Co. Ltd., Apitope International NV, BrainStorm Cell Therapeutics Inc., Roche Diagnostics, InnoCare Pharma, NervGen Pharma Corp., Receptos Inc., Biogen Idec International GmbH, MedDay Pharmaceuticals SA, Genentech Inc., Roche Holding AG.

North America was the largest region in the multiple sclerosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the multiple sclerosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have increased cost pressures in the multiple sclerosis treatment market by raising prices for monoclonal antibodies, immunomodulators, injectable devices, and specialty drug ingredients. Advanced disease-modifying therapies are most affected, especially in North America and Europe where biologics and APIs are often imported. Hospitals and specialty clinics face higher treatment acquisition costs. However, tariffs are encouraging domestic biologics production and local pharmaceutical innovation, supporting long-term therapy availability.

The multiple sclerosis treatment market research report is one of a series of new reports that provides multiple sclerosis treatment market statistics, including multiple sclerosis treatment industry global market size, regional shares, competitors with a multiple sclerosis treatment market share, detailed multiple sclerosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the multiple sclerosis treatment industry. This multiple sclerosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Multiple sclerosis (MS) treatment encompasses the medical approaches and therapies used to control symptoms, slow disease progression, and enhance the quality of life for individuals with multiple sclerosis, a chronic autoimmune disorder affecting the central nervous system. It involves disease-modifying therapies (DMTs) as well as symptomatic treatments that address issues such as fatigue, muscle spasticity, and mobility difficulties. These therapies are intended to preserve neurological function and improve the patient’s overall well-being.

The primary types of multiple sclerosis treatment include immunomodulators, corticosteroids, symptomatic therapies, monoclonal antibodies, and oral therapies. Immunomodulators are medications that modify immune system activity to decrease inflammation and reduce MS relapses, with commonly used examples being interferon beta and glatiramer acetate. The various disease categories include clinically isolated syndrome, relapsing-remitting multiple sclerosis, primary progressive multiple sclerosis, and secondary progressive multiple sclerosis. These treatments are delivered through oral, injectable, or intravenous routes and are distributed via channels such as hospital pharmacies, retail pharmacies, and online pharmacies, serving end users including hospitals, specialty clinics, homecare settings, and other healthcare providers.

The multiple sclerosis treatment market consists of sales of products including disease-modifying therapies, synthetic polypeptides, cannabinoid-based therapies, interferon beta products, and plasma exchange. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.